ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Budapest, Budapest

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Budapest, Budapest, HUN:

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer (EL1SSAR)

with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Nab-Paclitaxel
Drug: Atezolizumab

Phase 3

Roche
Roche

Tatabanya, Hungary and 75 other locations

mg twice per day. Capivasertib or placebo could be interrupted for up to 4 weeks for toxicity.Tumor assessments included computed tomograph...

Active, not recruiting
Metastatic Breast Cancer
Drug: AZD5363
Drug: Paclitaxel

Phase 2

Queen Mary University of London

Budapest, Hungary and 45 other locations

This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...

Active, not recruiting
Breast Cancer
Drug: Paclitaxel
Drug: Eribulin mesylate

Phase 3

AstraZeneca
AstraZeneca

Budapest, Hungary and 228 other locations

previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Sacituzumab Govitecan-hziy
Drug: Paclitaxel

Phase 3

Gilead Sciences
Gilead Sciences

Budapest, Hungary and 516 other locations

for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...

Enrolling
Breast Cancer
Drug: Tobemstomig
Drug: Nab-Paclitaxel

Phase 2

Roche
Roche

Tatabanya, Hungary and 109 other locations

after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Pembrolizumab
Drug: Gemcitabine

Phase 2

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Budapest, Hungary and 121 other locations

with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...

Active, not recruiting
Triple Negative Breast Cancer
PD-L1 Positive
Drug: Pembrolizumab
Drug: Carboplatin

Phase 3

Gilead Sciences
Gilead Sciences

Budapest, Hungary and 505 other locations

with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who car...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: nab-paclitaxel
Drug: placebo

Phase 3

Novartis
Novartis

Budapest, Hungary and 76 other locations

III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Placebo

Phase 3

AstraZeneca
AstraZeneca

Budapest, Hungary and 260 other locations

with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of ...

Active, not recruiting
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Biological: Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)
Biological: Acasunlimab

Phase 1, Phase 2

Genmab
Genmab

Törökbálint, Hungary and 56 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems